The stock price of OKYO Pharma Limited (NASDAQ: OKYO) has jumped by 5.80 compared to previous close of 2.07. Despite this, the company has seen a gain of 16.49% in its stock price over the last five trading days. accessnewswire.com reported 2025-06-11 that Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research update on OKYO Pharma Limited (NASDAQ:OKYO), an emerging player in the fast-growing ophthalmic drugs segment. The Goldman report carries a price target.
Is It Worth Investing in OKYO Pharma Limited (NASDAQ: OKYO) Right Now?
Moreover, the 36-month beta value for OKYO is -0.25. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OKYO is 22.24M and currently, short sellers hold a 0.79% of that float. On June 11, 2025, OKYO’s average trading volume was 125.39K shares.
OKYO’s Market Performance
The stock of OKYO Pharma Limited (OKYO) has seen a 16.49% increase in the past week, with a 58.70% rise in the past month, and a 45.03% gain in the past quarter. The volatility ratio for the week is 5.31%, and the volatility levels for the past 30 days are at 6.48% for OKYO. The simple moving average for the past 20 days is 21.88% for OKYO’s stock, with a 79.98% simple moving average for the past 200 days.
OKYO Trading at 45.05% from the 50-Day Moving Average
After a stumble in the market that brought OKYO to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 2.82% of gains for the given period.
#####
#####
Stock Fundamentals for OKYO
The total capital return value is set at 0.0.
Based on OKYO Pharma Limited (OKYO), the company’s capital structure generated -0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -0.13.
Currently, EBITDA for the company is 15745.87 with net debt to EBITDA at 295.2. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.28.
Conclusion
To wrap up, the performance of OKYO Pharma Limited (OKYO) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
